Vitura Health (ASX: VIT) announced its Doctors on Demand (DoD) division has achieved a major operational milestone, completing over 1 million consultations since the start of FY2024.
This growth has been underpinned by a clear shift towards sustained EBITDA profitability.
Revenue for DoD increased substantially, rising from $14.1 million in Q1-Q3 FY2024 to $21.6 million in Q1-Q3 FY2026, representing a 54% uplift over the period.
Margins have also seen significant improvement, moving from -3% in FY2024 to 5% in FY2026.
The network of qualified and vetted doctors supporting the platform has also expanded from approximately 200 at the time of acquisition in October 2023 to more than 320 as at 20 April 2026.
Revenue Growth and Efficiency Gains
Operational expenditure within Doctors on Demand has been prudently managed, with a 4% reduction year-on-year contributing to a 14% improvement in efficiency across the division.
The company is confident in DoD's trajectory, projecting continued revenue and EBITDA growth into FY2027.
This outlook suggests potentially another full-year record for the division.
These efficiency improvements and operational leverage are clearly identified as key drivers behind the improved financial performance and positive momentum.
Context: Recent Strategic Moves
Vitura has been actively expanding its digital health ecosystem.
In February 2026, the company announced the integration of Candor Medical, which added access to an additional 15,000 patients.
A strategic distribution agreement was also inked with MedReleaf Australia in March 2026 that is anticipated to add up to $15 million in incremental annual revenue over time.
Despite these positive developments and overall revenue growth to $67.9 million in H1 FY26, Vitura's H1 FY26 results highlighted broader market challenges.
Profitability was pressured by medicinal cannabis price compression and higher doctor costs, with normalised EBITDA falling to $1.9 million from $4.6 million in the prior corresponding period.
The company is also navigating a leadership transition, with Justin James appointed as the new Chief Executive Officer, effective 1 June 2026.
Challenges and Outlook
While Doctors on Demand demonstrates robust operational metrics, the company acknowledges ongoing profitability pressure across its wider operations.
This is primarily attributed to market conditions, including sector-wide medicinal cannabis price compression and increased doctor costs.
In response, Vitura is actively implementing cost reduction measures including a 10% reduction in total OPEX, which is expected to deliver $2.8 million in annualised run-rate savings.
Forward-looking statements from the company express expectations for continued growth in both revenue and EBITDA for the Doctors on Demand division into FY2027, signalling confidence in its telehealth strategy.
